Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing technology, using its patented gene sequencing platform to ...

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

Genesis announced that it has completed its second successful human transplant with a genetically engineered pig kidney, with ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.A novel ...

The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene ...